Chinese biotech firm Bao Pharma closes over $100m in Series B round

Chinese biotech firm Bao Pharma closes over $100m in Series B round

Laboratory equipment. Photo: Pixabay

Chinese biotech firm Bao Pharmaceuticals has secured over $100 million in a Series B round of financing led by Oriental Fortune Capital to ramp up its efforts to develop and commercialise recombinant protein drugs and antibody drugs.

Haitong Innovation Captial Management, the private equity (PE) arm of China’s Haitong Securities, as well as Chinese domestic investment companies Sun Rock Capital Management and Jintong Capital participated in the deal. Existing investors CenterLab and Findowin Capital re-upped in the round, the lead investor announced in a statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter